Telix Announces Proposed Acquisition of QSAM Biosciences
Filed with ASX · · 3 pages · English
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study
- Telix Completes Acquisition of Lightpoint Medical
- ProstACT SELECT Study of TLX591 Positive Interim Readout
- Q3 2023 Business Update to Accompany Quarterly Results
- Activities Report and Appendix 4C - September 2023 Quarter
Later from Telix Pharmaceuticals
- Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
- Telix Plans U.S. Registered Public Offering and Listing
- JP Morgan Healthcare Conference and Trading Update
- JP Morgan Healthcare Conference Presentation
- Presentation to Accompany QSAM Acquisition
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals